Loading...

Jeremy Pettus

TitleAssistant Clinical Professor
InstitutionUniversity of California San Diego
DepartmentMedicine
Address9500 Gilman Drive #9111-G
La Jolla CA 92093
Phone858-246-2160
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pettus J, Santos Cavaiola T, Edelman SV. Recommendations for Initiating Use of Afrezza Inhaled Insulin in Individuals with Type 1 Diabetes. Diabetes Technol Ther. 2018 Jun; 20(6):448-451. PMID: 29901406.
      View in: PubMed
    2. Cavaiola TS, Pettus J. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors. Diabetes Metab Syndr Obes. 2018; 11:133-148. PMID: 29695924.
      View in: PubMed
    3. Blumer I, Pettus J, Santos Cavaiola T. Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations. Postgrad Med. 2018 Mar 20; 1-6. PMID: 29521173.
      View in: PubMed
    4. Yale JF, Pettus J, Brito-Sanfiel M, Lavalle-Gonzalez F, Merino-Trigo A, Stella P, Chevalier S, Buzzetti R. The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3. PLoS One. 2018; 13(1):e0190579. PMID: 29370218.
      View in: PubMed
    5. Pettus J, Reeds D, Cavaiola TS, Boeder S, Levin M, Tobin G, Cava E, Thai D, Shi J, Yan H, Bautista E, McMillan J, Unger R, Henry RR, Klein S. Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May; 20(5):1302-1305. PMID: 29283470.
      View in: PubMed
    6. Pettus J, Von Herrath M. The shifting paradigm of a "cure" for type 1 diabetes: is technology replacing immune-based therapies? Acta Diabetol. 2018 Feb; 55(2):117-120. PMID: 29188386.
      View in: PubMed
    7. Goldman J, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017 10; 33(10):1821-1831. PMID: 28537449.
      View in: PubMed
    8. Henry RR, Dandona P, Pettus J, Mudaliar S, Xu J, Hansen L. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting ß-hydroxybutyrate levels in a phase IIa pilot study. Diabetes Obes Metab. 2017 06; 19(6):814-821. PMID: 28098426.
      View in: PubMed
    9. Pettus J. TIME TO GET SERIOUS ABOUT INSULIN TIMING. Endocr Pract. 2017 04 02; 23(4):503-505. PMID: 28156157.
      View in: PubMed
    10. Pettus J, Edelman SV. Differences in Use of Glucose Rate of Change (ROC) Arrows to Adjust Insulin Therapy Among Individuals With Type 1 and Type 2 Diabetes Who Use Continuous Glucose Monitoring (CGM). J Diabetes Sci Technol. 2016 09; 10(5):1087-93. PMID: 27044518.
      View in: PubMed
    11. Pettus J, Edelman SV. Recommendations for Using Real-Time Continuous Glucose Monitoring (rtCGM) Data for Insulin Adjustments in Type 1 Diabetes. J Diabetes Sci Technol. 2017 01; 11(1):138-147. PMID: 27530720.
      View in: PubMed
    12. Ahn D, Pettus J, Edelman S. Unblinded CGM Should Replace Blinded CGM in the Clinical Management of Diabetes. J Diabetes Sci Technol. 2016 05; 10(3):793-8. PMID: 26884422.
      View in: PubMed
    13. Pettus J, Edelman SV. Use of Glucose Rate of Change Arrows to Adjust Insulin Therapy Among Individuals with Type 1 Diabetes Who Use Continuous Glucose Monitoring. Diabetes Technol Ther. 2016 Feb; 18 Suppl 2:S234-42. PMID: 26784128; PMCID: PMC4717500.
    14. Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016 09; 32(6):478-96. PMID: 26509843.
      View in: PubMed
    15. Pettus J, Price DA, Edelman SV. HOW PATIENTS WITH TYPE 1 DIABETES TRANSLATE CONTINUOUS GLUCOSE MONITORING DATA INTO DIABETES MANAGEMENT DECISIONS. Endocr Pract. 2015 Jun; 21(6):613-20. PMID: 25716635.
      View in: PubMed
    16. Edelman S, Pettus J. Challenges associated with insulin therapy in type 2 diabetes mellitus. Am J Med. 2014 Oct; 127(10 Suppl):S11-6. PMID: 25282008.
      View in: PubMed
    17. Sarikonda G, Sachithanantham S, Pettus J, Rodriguez-Calvo T, Phatak S, Edelman S, von Herrath M. Higher proinflammatory cytokine production and spontaneous activation in some type 1 and type 2 diabetic subjects. Clin Immunol. 2014 Nov; 155(1):27-9. PMID: 25173803.
      View in: PubMed
    18. Pettus J, Stenger P, Schachner HC, Dunne N, Parkes JL, Pardo S, Edelman SV. Testing versus guessing blood glucose values: impact on self-care behaviors in type 2 diabetes. Curr Med Res Opin. 2014 Sep; 30(9):1795-802. PMID: 24889281.
      View in: PubMed
    19. Henry RR, Mudaliar S, Ciaraldi TP, Armstrong DA, Burke P, Pettus J, Garhyan P, Choi SL, Jacober SJ, Knadler MP, Lam EC, Prince MJ, Bose N, Porksen N, Sinha VP, Linnebjerg H. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014 Sep; 37(9):2609-15. PMID: 24947791.
      View in: PubMed
    20. Sarikonda G, Pettus J, Phatak S, Sachithanantham S, Miller JF, Wesley JD, Cadag E, Chae J, Ganesan L, Mallios R, Edelman S, Peters B, von Herrath M. CD8 T-cell reactivity to islet antigens is unique to type 1 while CD4 T-cell reactivity exists in both type 1 and type 2 diabetes. J Autoimmun. 2014 May; 50:77-82. PMID: 24387802.
      View in: PubMed
    21. Sarikonda G, Pettus J, Sachithanantham S, Phatak S, Miller JF, Ganesan L, Chae J, Mallios R, Edelman S, Peters B, von Herrath M. Temporal intra-individual variation of immunological biomarkers in type 1 diabetes patients: implications for future use in cross-sectional assessment. PLoS One. 2013; 8(11):e79383. PMID: 24223938; PMCID: PMC3817042.
    22. Pettus J, von Herrath M. Keeping the patient perspective: Where are we in the world of type 1 diabetes? Clin Immunol. 2013 Dec; 149(3):265-7. PMID: 24012473.
      View in: PubMed
    23. Pettus J, Hirsch I, Edelman S. GLP-1 agonists in type 1 diabetes. Clin Immunol. 2013 Dec; 149(3):317-23. PMID: 23643354.
      View in: PubMed